Safety of FLT3 inhibitors in patients with acute myeloid leukemia

References

• Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA. 2009;106(31):12950–12955.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood. 2008;111(5):2527–2537.
   PubMed Web of Science ®Google Scholar
• Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
   PubMed Web of Science ®Google Scholar
• Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205–4214.
   PubMed Web of Science ®Google Scholar
• Weis TM, Marini BL, Bixby DL, et al. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;141:125–138.
   PubMed Web of Science ®Google Scholar
• Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. mol Cancer Ther. 2017;16(6):991–1001.
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD, et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104(4):1145–1150.
   PubMed Web of Science ®Google Scholar
• Mosquera O, Bao P, Mosquera T, et al. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Minerva Med. 2020;111. doi: https://doi.org/10.23736/S0026-4806.20.06989-X.
   Google Scholar
• Rydapt®. Drug data sheet. Eudra; [Internet]. [cited 2020, May 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt [ cited 2020, May 26].
   Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al., Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5): 454–464.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840–851.
   PubMed Web of Science ®Google Scholar
• Midostaurin BC cancer agency cancer drug manual. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Midostaurin_monograph.pdf .
   Google Scholar
• Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123(1):94–100.
   PubMed Web of Science ®Google Scholar
• Johan A, Corrado G, Roger J, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in leukaemia. J Antimicrob Chemother. 2018;73:3221–3230.
   PubMed Web of Science ®Google Scholar
• Stemler J, Koehler P, Maurer C, et al. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. Ann Hematol. 2020 Jul;99(7):1429–1440. Epub 2020 Jun 8. PMID: 32514626; PMCID: PMC7316674.
   PubMed Web of Science ®Google Scholar
• Lindsay J, Teh BW, Micklethwaite K, et al. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019;32(6):538–545.
   PubMed Web of Science ®Google Scholar
• Schlafer D. Management of Midostaurin-CYP3A4 drug-drug interactions in patients with acute myeloid leukemia. Oncology (Williston Park). 2019;33(7):629381.
   PubMed Web of Science ®Google Scholar
• Noxafil® (posaconazole)—prescribing information (2019). Merck & Co Inc., Whitehouse Station.
   Google Scholar
• Rothe A, Classen A, Carney J, et al. Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: a retrospective analysis. Eur J Haematol. 2019;104(4):291–298.
   Web of Science ®Google Scholar
• Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416.
   PubMed Web of Science ®Google Scholar
• Park H, Youk J, Shin DY, et al. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. BMC Cancer. 2019;19(1):358.
   PubMedGoogle Scholar
• Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Inf Secur. 2016;73(5):496–505.
   Google Scholar
• Epstein DJ, Seo SK, Huang YT, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. J Inf Secur. 2018;77(3):227–234.
   Google Scholar
• Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and Young adults with acute myeloid leukemia: a randomized clinical trial. Jama. 2019;322(17):1673–1681.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50(1):143–147.
   PubMed Web of Science ®Google Scholar
• Groll AH, Stergiopoulou T, Roilides E, et al. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005;14(4):489–509.
   PubMed Web of Science ®Google Scholar
• Rosa PDD, Ramirez-Castrillon M, Borges R, et al. Epidemiological aspects and characterization of the resistance profile of Fusarium spp. in patients with invasive fusariosis. J Med Microbiol. 2019;68(10):1489–1496.
   PubMed Web of Science ®Google Scholar
• Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31(2):17–29.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–e421.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–2085.
   PubMed Web of Science ®Google Scholar
• Bose P, McCue D, Wurster S, et al. Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective. Phase II Study Clin Infect Dis. 2020;doi: https://doi.org/10.1093/cid/ciaa358
   Google Scholar
• CRESEMBA® (Isavuconazoium)—prescribing information (2019). Astellas Pharma US Inc., Northbrook.
   Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
   PubMed Web of Science ®Google Scholar
• Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough invasive fungal infections on Isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018;67(7):1142–1143.
   PubMed Web of Science ®Google Scholar
• Rausch CR, DiPippo AJ, Bose P, et al. Breakthrough fungal infections in patients with leukemia receiving Isavuconazole. Clin Infect Dis. 2018;67(10):1610–1613.
   PubMed Web of Science ®Google Scholar
• Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020 Feb 14;70(5):723–730. PMID: 30958538; PMCID: PMC7931837.
   PubMed Web of Science ®Google Scholar
• Stern A, Su Y, Lee YJ, et al. A single-Center, open-Label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020 Jun;26(6):1195–1202. Epub 2020 Feb 20. PMID: 32088367; PMCID: PMC8210627.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011;19(1):19–26.
   PubMed Web of Science ®Google Scholar
• A. Sierra J, Montesinos P, Thomas X. 632 phase 3b study assessing the safety and efficacy of midostaurin in younger and older patients with newly diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy. https://ash.confex.com/ash/2020/webprogram/Paper136083.html
   Google Scholar
• Burchert A, Bug G, Finke J, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial Blood. 2018;132 (Supplement 1):661. Available from: https://doi.org/10.1182/blood-2018-99-112614
   Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–844.
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare. 2018. NEXAVAR (sorafenib). U.S. food and drug administration. [Internet]. [ cited 2020 Aug 21]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
   Google Scholar
• Liu T, Ivaturi V, Sabato P, et al. Sorafenib dose recommendation in acute myeloid leukemia based on exposure-FLT3 relationship. Clin. Transl. Sci. 2018;11(4):435–443.
   PubMed Web of Science ®Google Scholar
• Xuan L, Wang Y, Huang F. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201–1212.
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Barete S, et al. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf. 2010 Mar;9(2):275–287. PMID: 20078249.
   PubMed Web of Science ®Google Scholar
• Sorafenib BC Cancer Agency Cancer Drug Manual. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Sorafenib_monograph_1Dec2014.pdf
   Google Scholar
• Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7(4):127–134.
   PubMed Web of Science ®Google Scholar
• Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592–596.
   PubMed Web of Science ®Google Scholar
• Beldner M, Jacobson M, Burges GE, et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist. 2007;12(10):1178–1182.
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6(4):219–228.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10;28(11):1856–1862. Epub 2010 Mar 8. PMID: 20212254; PMCID: PMC2930809.
   PubMed Web of Science ®Google Scholar
• Park IK, Mundy-Bosse B, Whitman SP, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382–2389.
   PubMed Web of Science ®Google Scholar
• Park IK, Mishra A, Chandler J, et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood. 2013;121(11):2064–2073.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma. XOSPATA (gilteritinib). U.S. Food and drug administration; 2019 [Internet].  [cited 2020 Aug 21]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf.
   Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al., Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18): 1728–1740.
   PubMed Web of Science ®Google Scholar
• Jianke L, Bresnahan G, Sanga M, et al., Absorption, metabolism, and excretion of quizartinib (AC220), a FLT3 tyrosine kinase inhibitor for treatment of acute myeloid leukemia, in healthy male volunteers. Blood. 2012;120(21):4327.
   Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al., Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, openlabel, phase 3 trial. Lancet Oncol. 2019;20(7): 984–997.
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Al Hamed R, Malard F, et al. Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. Ther Adv Hematol. 2019;10:2040620719882666.
   Web of Science ®Google Scholar
• Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132(6):598–607.
   PubMed Web of Science ®Google Scholar
• 2014. Study of crenolanib in combination with chemotherapy in patients with relapsed or refractory acute myeloid leukemia and activating FLT3 mutations. ClinicalTrials.gov, [ cited 2020 Aug 19. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02298166
   Google Scholar
• Short NJ, Kantarjian H, Ravandi F, et al. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol. 2019;10:2040620719827310.
   Web of Science ®Google Scholar
• Stone RM, Wang ES, Goldberg AD, et al. Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML. J Clin Oncol. 2019;37(15_suppl): TPS7068.
   Web of Science ®Google Scholar
• Altman JK, Foran JM, Pratz KW, et al. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213–221.
   PubMed Web of Science ®Google Scholar
• Pratz K, Cherry M, Altman JK, et al. Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed Acute Myeloid Leukemia (AML). Blood. 2017;130:722.
   PubMed Web of Science ®Google Scholar
• Erba HP, Levis MJ, Sekeres MA, et al. Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. J Clin Oncol. 2016;34: TPS7073.
   Web of Science ®Google Scholar
• Luger SM, Sun Z, Loghavi S, et al. Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated Acute Myeloid Leukemia (AML). Blood. 2019;134(Supplement_1):1309.
   Google Scholar
• Naina HV, Patnaik MM, Harris S. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361: 2578. author reply 2578.
   PubMedGoogle Scholar
• Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD Mutated Acute Myeloid leukemia. Am J Hematol. 2018;93(9):1136–1141.
   PubMed Web of Science ®Google Scholar
• A study of ASP2215 (gilteritinib) by itself, ASP2215 combined with azacitidine or azacitidine by itself to treat adult patients who have recently been diagnosed with acute myeloid leukemia with a FLT3 gene mutation and who cannot receive standard chemotherapy. ClinicalTrials.gov; 2016 [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02752035 [ cited 2020 Aug 2].
   Google Scholar
• Esteve J, Schots R, Del Castillo TB, et al. Multicenter, open-Label, 3-Arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the safety cohort. Blood. 2018;132:2736.
   Web of Science ®Google Scholar
• Maziarz RT, Patnaik MM, Scott BL, et al. Radius: phase A. 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITDMutated AML. Blood. 2018;132:662.
   PubMed Web of Science ®Google Scholar
• Metzelder SK, Schroeder T, Lu¨ Bbert M, et al. Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem-cell transplantation. Eur J Cancer. 2017;86:233–239.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Li S, Fathi AT, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496–504.
   PubMed Web of Science ®Google Scholar
• Mark J, Chen Y-B, Mehdi H, et al. FLT3 inhibitor maintenance after allogeneic transplantation: is a Placebo-Controlled, randomized trial ethical? J clin oncol. 2019 Jul 1;37(19):1604-1607. DOI: https://doi.org/10.1200/JCO.19.00321. Epub 2019 Apr 29.
   Google Scholar
• Levis MJ, Hamadani M, Logan B, et al. A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. J Clin Oncol. 2018;3615_suppl. Available from: https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS7075
   Google Scholar
• Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014 Feb;49(2):168-73. DOI: https://doi.org/10.1038/bmt.2013.107. Epub 2013 Jul 29.
   Google Scholar
• Novartis Pharmaceuticals. Neoral (Cyclosporine modified) Package Insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
   Google Scholar
• Novartis Pharmaceuticals. Rydapt (Midostaurin) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.
   Google Scholar
• Mancini R, LaMontagne L, Williams T, et al. Midostaurin and cyclosporine drug interaction: a case report. J Clin Pharm Ther. 2020 Apr;45(2):384–387. Epub 2019 Nov 29. PMID: 31782821.
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Acute leukaemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599–1606.
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110–3118.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 2007;21(8):1763–1772.
   PubMed Web of Science ®Google Scholar
• Isidori A, Cerchione C, Daver N, et al. Immunotherapy in Acute Myeloid Leukemia: where we stand. Front Oncol. 2021 May 10;11:656218. eCollection 2021. PMID: 34041025.
   PubMedGoogle Scholar
• Cerchione C, Romano A, Daver N, et al. IDH1/IDH2 inhibition in Acute Myeloid Leukemia. Front Oncol. 2021 Mar 29;11:639387. eCollection 2021. PMID: 33898313.
   PubMedGoogle Scholar
• Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, et al. Personalized survival prediction of patients with Acute Myeloblastic Leukemia using gene expression profiling. Front Oncol. 2021 Mar 29;11:657191. eCollection 2021. PMID: 33854980.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Martino G, Cardinali V, et al. Enasidenib and ivosidenib in AML. Minerva Med. 2020 Oct;111(5):411–426. Epub 2020 Sep 21. PMID: 32955829.
   PubMed Web of Science ®Google Scholar
• Gottardi M, Sperotto A, Ghelli Luserna Di Rorà A, et al. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future. Minerva Med. 2020 Oct;111(5):395–410. Epub 2020 Sep 21. PMID: 32955828.
   PubMed Web of Science ®Google Scholar
• Cafaro A, Giannini MB, Silimbani P, et al. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. Minerva Med. 2020 Oct;111(5):455–466. Epub 2020 Sep 21. PMID: 32955826.
   PubMed Web of Science ®Google Scholar
• Palmieri R, Buccisano F, Maurillo L, et al. Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. Minerva Med. 2020 Oct;111(5):386–394. Epub 2020 Sep 21. PMID: 32955825.
   PubMed Web of Science ®Google Scholar
• Takami A. Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol. 2018;107(5):513–518.
   PubMed Web of Science ®Google Scholar
• Marconi G, Giannini MB, Bagnato G, et al. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Expert Opin Drug Saf. 2021;20(7):791–799. epub ahead of print.
   PubMed Web of Science ®Google Scholar